Video & Transcript : 'generic drugs' :
Page 5 of 500
MN
Minnesota 2025-2026 Regular Session
Committee on Commerce and Consumer Protection - 03/11/25
Commerce and Consumer Protection
Transcript Highlights:
- drugs and biosimilars in an effort to increase adoption of generic drugs and biosimilar drugs.
- Today, about 90% of all prescription drugs dispensed are generic drugs.
- There's been a high adoption rate of generic drugs.
- About 90% of all prescription drugs dispensed are generic drugs.
- There's been a high adoption rate of generic drugs.
Committee:
Senate Commerce and Consumer Protection
MA
Massachusetts 2025-2026 Regular Session
Joint Committee on Financial Services Jun 21st, 2026 at 10:30 am
Joint Committee on Financial Services
Transcript Highlights:
- If a hospital can buy that drug at a 340B discount, say $100,000, and then resell the drug to Medicare
- Currently, PBMs favor highly rebated drugs over cheaper alternatives, with no rebates for generics or
- value for these high-cost drugs.
- for these high-cost drugs.
- Specialty drugs account for roughly 2% of drugs.
Committee:
Joint Joint Committee on Financial Services
Summary:
The committee held a lengthy hearing on a large docket of pharmacy and drug-pricing bills, with most testimony focused on PBM reform, 340B drug discount program protections, specialty medication access, and medication adherence. Chair James Murphy and Senator Paul Feeney opened the hearing and took testimony from legislators, patient advocates, pharmacists, health center leaders, industry representatives, and policy groups. Several speakers described delays, denials, high out-of-pocket costs, and pharmacy closures tied to PBM practices, while others emphasized the importance of community health centers and independent pharmacies in serving patients.
On the 340B program, supporters including Senator Eldridge, Senator Payano, Community Care Cooperative, Fenway Health, the Massachusetts League of Community Health Centers, and several community health center leaders argued that bills such as H. 1107 and S. 819 would stop discriminatory PBM and manufacturer practices, preserve contract pharmacy access, and protect safety-net providers that say they reinvest savings into care, pharmacy expansion, interpreter services, behavioral health, and other services. Opponents including PhRMA, the Community Liver Alliance, and a public policy analyst argued the program lacks transparency and accountability, has grown beyond its original purpose, and may benefit large hospitals and for-profit entities more than low-income patients. They urged more reporting and oversight rather than expanding protections.
On PBM reform, testimony supported bills including H. 1157, H. 1234, S. 724, S. 831, and related measures that would require rebate pass-through, ban spread pricing, limit steering to PBM-owned pharmacies, and improve reimbursement for community pharmacies. Independent pharmacists and patients said current PBM practices raise costs, create administrative burdens, and threaten access to local pharmacies. PCMA, representing PBMs, opposed the reforms, arguing PBMs lower costs, that plan sponsors choose to contract with them, and that the Health Policy Commission and CHIA should complete their ongoing study before new mandates are adopted. The committee also heard support for H. 1322 and S. 734 on specialty medications, and for H. 781 and H. 1305 on medication synchronization to improve adherence. No votes or formal actions were taken during the hearing.
MA
Massachusetts 2025-2026 Regular Session
Joint Committee on Health Care Financing Jun 21st, 2026 at 11:00 am
Joint Committee on Health Care Financing
Transcript Highlights:
- On behalf of insurance companies, they determine who is eligible, what drugs are covered, what drug a
- They are managing rising drug costs.
- of the drugs, and the distribution of the drugs?
- , not the net price of the drug.
- among drugs happened very quickly.
Summary:
The Joint Committee on Health Care Financing held a public hearing on a broad set of health care bills focused on cost, market oversight, pharmaceutical access, transparency, hospital closures, and pharmacy access. Chairs John Lawn and Cindy Friedman opened by emphasizing recent health care reforms and the need for further action on the drug supply chain, PBMs, private equity, and affordability. The committee heard testimony on several measures, including a Betsy Lehman Center bill to make technical changes and create a permanent trust account for federal and private funding, and bills on hospital profits and fairness, hospital closures and health planning, pharmacy deserts, and health care market oversight and pharmaceutical access. No votes were taken during the hearing.
On the hospital profits bill, physicians and labor advocates strongly supported capping hospital CEO compensation at 50 times the lowest-paid worker, requiring greater financial transparency, and directing penalties from high-margin public hospitals into a Medicaid reimbursement fund. Testifiers argued that executive pay is excessive while frontline staff and safety-net services are under strain. Committee members raised concerns about unintended consequences, including whether hospitals might shift workers to contract status or lose executive talent, and whether the bill would actually direct money to the safety net. Supporters responded that the measure is one piece of a larger effort and that the bill’s Medicaid reimbursement provisions would help underserved hospitals.
Testimony on market oversight and pharmaceutical access centered on rising health care and drug costs, PBM practices, and the proposal to give the Health Policy Commission authority to set upper payment limits for certain drugs. Consumer advocates, disability advocates, an independent pharmacist, the Attorney General’s office, and others supported stronger oversight, citing premium increases, affordability problems, and the impact of high drug prices on patients and community pharmacies. Pharma and some industry witnesses opposed parts of the bill, warning that upper payment limits could disrupt access, create legal issues, and fail to address the broader supply chain. The committee also heard support for stronger hospital closure notice and public hearing requirements, and for a pharmacy deserts bill aimed at identifying and addressing closures like the one in Roxbury that affected thousands of patients.
WA
Washington 2025-2026 Regular Session
House Health Care & Wellness Jan 20th, 2026 at 01:30 pm
Health Care & Wellness
Transcript Highlights:
- The program generates savings for covered entities, called 340B savings, because once they buy the drugs
- First, the statute prohibits a covered entity from requesting a Medicaid drug rebate for a drug that
- NCSL has been tracking prescription drug legislation for about a decade now through our drug legislation
- Two, the median launch price of drugs has increased 20% year over year since 2008, and drug therapies
- place that reduces the cost of drugs to our members, and that those are lost when drugs are purchased
Committee:
House Health Care & Wellness
Keywords:
340B drug pricing, healthcare access, patient rights, discounted medications, manufacturer limitations, health professions, plasma donation, physician substitutes, medical regulation, nursing titles, healthcare, regulation, professional standards, licensure, accreditation, opioid treatment, health services, fee authority, public health
US
US Federal 2025-2026 Regular Session
Hearings to examine the nomination of Martin Makary, of Virginia, to be Commissioner of Food and Drugs, Department of Health and Human Services. Mar 6th, 2025 at 09:00 am
Health, Education, Labor, and Pensions Committee
Transcript Highlights:
- And one way that we can do this is by making it easier for generic and biosimilar drugs to come to market
- McCary, when we met, you and I discussed the importance of increasing generic drug competition.
- If confirmed, will you work with me to speed the approval of generic drugs at FDA to lower drug costs
- Drug Applications Act, which would allow the FDA to communicate more transparently with generic drug
- We have a bill, Skinny Labels Big Savings Act, that helps more generic drugs, more of that competition
Keywords:
nominations, labor, health, veterans, Social Security, Elon Musk, transparency, government accountability
Summary:
The meeting primarily focused on various executive nominations and their implications on labor and health affairs. Significant discussions surrounded the nomination of Mr. Sonderling as the Deputy Secretary of Labor, with members expressing concerns about workforce cuts affecting veterans and Social Security employees. There was also a debate led by a member regarding the authority and influence of private individuals, specifically citing Elon Musk's involvement in government decisions. Such discussions raised questions about transparency and accountability within governmental agencies, leading to a proposal for Mr. Musk to provide testimony before the committee.
NH
New Hampshire 2025 Regular Session
House Finance Division III (03/12/2025)
Transcript Highlights:
- All of those types of drugs—provider-administered drugs, infusions, IVs—those types of drugs.
- All of those types of drugs—provider-administered drugs, infusions, IVs—those types of drugs.
- All of those types of drugs—provider-administered drugs, infusions, IVs—those types of drugs.
- Every prescription drug has a National Drug Code; it’s an identifier for the drug, right?
- Cost Plus Drugs, established by Mark Cuban, is largely a generic relabeling company that we could explore
Summary:
The working session focused on the New Hampshire Prescription Drug Affordability Board’s budget request and its recent work. Early discussion centered on a technical question about a statutory dedicated fund for donations: members asked why the budget did not show a line item for accepting donations, and DHHS CFO Nathan White explained that the statute already authorizes the fund, but because no revenue has been received yet, it does not appear in the budget. He said any future donations would go through the normal process under RSA 14:30-a, with fiscal committee and Governor and Council approval and a memo to the Department of Revenue Administration. The chair clarified that the account was not a prerequisite to soliciting donations, and White said the fund would supplement, not replace, General Fund support.
Kirk Williamson, the board’s executive director, then presented the board’s mission and budget. He said the governor’s budget provides about $256,500 in the first year and slightly more in the second, all General Funds, and that the board had distributed a technical amendment to continue the executive director position. He described the board’s role as analyzing prescription drug costs, identifying savings opportunities, monitoring market trends, promoting transparency, and making recommendations to the legislature and public payers. He also emphasized that the board operates publicly, with live-streamed meetings and a stakeholder advisory council that includes unions, state agencies, Medicaid, corrections, higher education, and other stakeholders.
A major topic was the board’s estimate of $6 million in potential savings, based on Medicare’s newly negotiated prices for 10 drugs. Williamson explained that the board used those federal negotiated prices as a benchmark to estimate what New Hampshire public payers might be missing by not having similar leverage, and said the board is trying to build evidence for future recommendations rather than directly setting prices. Members asked how those potential savings could become actual savings, and Williamson said the board is sharing findings through its advisory council and feedback loops, though it has not yet sent a formal recommendation letter to specific purchasers. He also discussed the difference between pharmacy-benefit spending, which relies heavily on PBM-negotiated rebates, and medical-benefit spending, which is administered differently and is being added to the board’s next report.
Williamson highlighted other work, including a model on Humira and a pending legislative effort to improve biosimilar competition, plus a proposed state-backed pharmacy savings card that would be no cost to the state and could save users about $240 per prescription based on Connecticut’s experience. No votes were taken during the session.
AZ
Transcript Highlights:
- In bulk drug substances.
- compounded under the Federal Food, Drug, and Cosmetic Act using a drug substance that is a receptor
- They're not approved as a drug.
- or an FDA-approved drug.
- See, the Auditor General, you give the Auditor General too much credit. I'm not dogging them.
Keywords:
trade offices, committee, Arizona commerce authority, stakeholder input, efficiency, Arizona-Sonora, Sonora, Mexico, trade commission, cross-border trade, bilateral trade, international trade, economic development, foreign relations, border economy, investment, infrastructure, business exchange, academic exchange, legislative commission
US
US Federal 2025-2026 Regular Session
Hearings to examine combating the opioid epidemic. Feb 26th, 2025 at 02:30 pm
Aging (Special) Committee
Transcript Highlights:
- The precursors of these drugs come from communist China and are bought by the evil drug cartels to make
- In the past year, fatal drug overdoses.
- Drug dealers cannot be let off easily.
- Drug cartels can quickly replace confiscated synthetic drugs with little effort and overhead, ensuring
- Do you see a direct correlation between over-the-counter drugs or prescription drugs that lead to addiction
Committee:
Senate Aging (Special) Committee
Keywords:
opioid crisis, overdose, naloxone, drug trafficking, law enforcement, treatment, prevention, older adults, Medicaid expansion
Summary:
The meeting convened to address the dire opioid crisis affecting communities nationwide, with a particular focus on the alarming rise of opioid use disorder among older adults. Key testimonies highlighted the critical need for a comprehensive approach that encompasses prevention, treatment, and strict law enforcement actions against drug traffickers. Sheriff Dennis Lima from Seminole County outlined successful strategies implemented in Florida, including increased access to naloxone and legislative changes to hold drug dealers accountable for overdoses. Various members expressed a united front on tackling this multifaceted issue, advocating for the expansion of Medicaid and better access to treatment as essential steps to curbing the epidemic.
AZ
Arizona 2026 Regular Session
02/18/2026 - House International Trade
House International Trade Committee of Reference
Transcript Highlights:
- In bulk drug substances.
- compounded under the Federal Food, Drug, and Cosmetic Act using a drug substance that is a receptor
- compounded under the Federal Food, Drug, and Cosmetic Act using a drug substance that is a receptor
- agonist used for obesity or weight management or a drug substance component of a similar drug approved
- or an FDA-approved drug.
Summary:
The committee began with a presentation from Berthold Barak Karlich of Benor Capital on investment and innovation from a European perspective. He argued that legacy in trade and innovation is about enabling future generations, not isolation, and highlighted Austria and Europe’s strengths in education, applied research, hidden-champion SMEs, and deep-tech. He also warned against economic nationalism and emphasized that entrepreneurship and cross-border trade create shared interests, peace, and long-term collaboration. In response to questions, he said Arizona had impressed him as a strong, international deep-tech hub, and he expressed interest in learning more about opportunities there.
The committee then considered HB 2746, which creates a study committee on trade offices under the Arizona Commerce Authority to review existing trade offices, gather stakeholder input, and report recommendations by December 31, 2028. Members discussed oversight of Arizona’s trade offices in countries including Mexico, Korea, Taiwan, Japan, Romania, and Germany, and the sponsor said the bill would help evaluate effectiveness while identifying new opportunities. The bill received a due pass recommendation on a 7-0 vote. HB 2750, which establishes the Arizona-Sonora Trade Commission with legislative appointees, also received a due pass recommendation after members discussed its role as a complement to executive-branch efforts; it passed 5-1 with one present.
The committee next heard HB 4036, a bill restricting the sale and distribution of compounded GLP-1 weight-loss drugs made with certain bulk drug substances and authorizing inspections by the State Board of Pharmacy. Supporters, including Novo Nordisk and the Partnership for Safe Medicines, argued the bill would address unsafe imported ingredients, impurities, misleading advertising, and a surge in mass compounding that they said exceeds the intent of compounding law. Opponents from the Arizona Pharmacy Association, compounding pharmacists, and a physician argued the bill would burden lawful compounders, raise costs, reduce access, and could harm patients who rely on compounded medications. After extensive debate, the committee failed to pass HB 4036 on a 5-5 vote.
Finally, the committee took up HB 2765, as amended by a strike-everything amendment creating a vapor product manufacturer licensing framework, fees, penalties, and Department of Revenue oversight. The sponsor said the measure was intended to address illegal smuggling of vape products and protect children, while opponents argued it would burden lawful businesses and that the real problem was illicit actors outside the regulated market. The transcript ends during the discussion of this bill, before a final vote is recorded.
KY
Kentucky 2025 Regular Session
Budget Review Subcommittee on Justice and Judiciary (8-20-25)
Transcript Highlights:
- Adult drug where it's needed most.
- Um, when I practiced, I had many of my clients go through drug court. Um, drug court works.
- </c> through drug court. Um drug court works. through drug court. Um drug court works.
- As Miss Collins said earlier, when somebody's in drug court, they're supervised by drug court.
- As Miss Collins said earlier, when somebody's in drug court, they're supervised by drug court.
Summary:
The subcommittee received an overview of Kentucky’s specialty courts from Audrey Collins of the Department of Specialty Courts and the Administrative Office of the Courts, along with testimony from Christian County District Judge Foster Cutoff. Collins described the mission and structure of drug, mental health, and veterans treatment courts, emphasizing therapeutic jurisprudence, individualized treatment, judicial oversight, and multidisciplinary teams. She said Kentucky currently has about 2,991 active participants across the three court types, with drug courts in all 120 counties, mental health courts in 17 counties, and veterans treatment courts in eight counties. She also highlighted reported outcomes such as 7,658 entrants and 4,384 successful completions from 2020 to 2024, a five-year average completion rate of 57%, and lower recidivism among graduates than the statewide average.
Collins also reviewed funding and costs, saying the department’s fiscal year 2025 budget was $18.6 million, with most of it from general funds, plus restricted and federal funds. She noted spending on personnel, treatment services, and drug testing, and said specialty courts allow participants to remain employed and meet obligations such as child support and restitution. She said participants paid more than $5.4 million in child support, restitution, and other court-related obligations over five years, and that a statewide evaluation by Morehead State University is underway. In response to questions, she said a dip in 2024 collections may have been affected by a case management system overhaul, and that court costs can be waived in some indigent cases while restitution is still required.
Judge Cutoff described veterans treatment court and mental health court in Christian County, saying the programs are especially important because of the nearby Fort Campbell military community and because they help veterans with PTSD, traumatic brain injury, substance use, and related issues. He said the courts rely heavily on staff, treatment providers, and the VA, which helps connect participants to benefits and therapy. He also said mental health court participants receive housing, benefits, and medication support, and that the programs can keep people out of jail and help them stabilize. Committee members asked about the legal basis and history of the courts, and Collins explained that Kentucky’s specialty courts began as pilot programs in the mid-1990s, shifted from federal support to state funding around 2008-2009, and are now largely state funded. No votes or formal actions were taken during the discussion.
US
US Federal 2025-2026 Regular Session
Hearings to examine the poisoning of America, focusing on fentanyl, its analogues, and the need for permanent class scheduling. Feb 4th, 2025 at 09:30 am
Senate Judiciary
Transcript Highlights:
- To have ties to drug cartels.
- Americans in general.
- Live in the right front pocket of the Mexican drug cartels? Mexican drug cartels?
- This was one of my priorities as Attorney General, but not because I was the Attorney General.
- Teens can now get drugs so easily.
Committee:
Senate Senate Judiciary
MN
Minnesota 2025-2026 Regular Session
Committee on Health and Human Services - 01/21/25
Health and Human Services
Transcript Highlights:
- </c><01:09:27.159><c> low</c> therefore compliance is generally low therefore compliance is generally
- </c> result of high prescription drug result of high prescription drug prices<01:18:10.960><c> um</c>
- </c><01:27:09.440><c> with</c><01:27:09.679><c> drugs</c> drugs revenues associated with drugs drugs
- are, as I said, high-cost drugs.
- are, as I said, high-cost drugs.
Committee:
Senate Health and Human Services
NH
Transcript Highlights:
- Then there's the drug dealer.
- </c><01:15:22.880><c> together</c> drugs two people using drugs together drugs two people using drugs
- And if people can be told, and the general public knows, that if they sell a drug, or as Senator Abis
- One and Schedule II drugs.
- so</c><01:51:13.000><c> it</c> got the drugs shared the drugs so it got the drugs shared the drugs so
Committee:
Senate Judiciary
FL
Florida 2025 Regular Session
March 20, 2025 - 11:30 AM
Transcript Highlights:
- Of that, $71 million was spent on generics, $553 million spent on brand-name drugs, and $547 million
- In 2024, anti-diabetic drugs were the most expensive drug class, accounting for 20% of the total drug
- The Vigilant Drug List is more modular, and it works by targeting high-cost brand medications and generics
- there's drug A, drug B, and drug C.
- Drug B is a little more expensive than Drug C, then it would say... ...expensive, Drug B is a little
Summary:
The Budget Committee met with a quorum and took up several bills. HB 677, relating to state-covered fertility preservation for employees undergoing cancer treatment, was introduced as coverage for egg and sperm preservation for up to three years, with an estimated fiscal impact of about $813,000. After brief questions and no public testimony or amendments, the bill passed unanimously and was reported favorably. The committee then considered CS/HB 59, which would reform Florida’s wrongful incarceration compensation process by extending the filing deadline from 90 days to two years, removing the clean-hands requirement, and allowing exonerees to choose between the state compensation process and a civil lawsuit; it was supported by the City of Flagler Beach and passed unanimously. CS/HB 1313, which recreates the Resilient Florida Trust Fund in the Department of Environmental Protection before its scheduled termination in 2025, also passed unanimously after supportive testimony from advocacy groups.
The committee received a lengthy presentation from the Department of Management Services on the State Group Insurance Program and the recent Revenue Estimating Conference. The presentation covered enrollment, revenues and expenditures, rising medical and pharmacy costs, emergency room utilization, GLP-1 drug spending, and options for tighter formulary and utilization management. Members asked about ER cost growth, GLP-1 coverage and copays, PBM oversight and potential conflicts, avoidable ER visits, cancer screening claims, dental and vision costs, specialty drug biosimilars, and possible savings from more restrictive pharmacy models. DMS said it would follow up on several questions and noted ongoing work on cancer coordination, preventive screening, biomarker testing, and a proposed member-facing benefits platform.
The committee also heard extensive testimony on HB 301, which would raise sovereign immunity caps from $200,000 per person and $300,000 per incident to $1 million and $3 million, align limitations periods with private claims, and allow government entities to settle above the caps without a claims bill. Local governments, school-related entities, and county and city associations opposed the bill, warning of major fiscal impacts, higher insurance costs, and pressure on services; several speakers urged smaller increases or a tiered approach. Proponents, including families affected by catastrophic injury or death, argued the current caps are too low and the claims bill process is inefficient and unfair. After debate, the bill passed on a recorded vote, with some members voting no, and was reported favorably.
MN
Minnesota 2025-2026 Regular Session
Lowering the High Cost of Healthcare | Senator Matt Klein May 1st, 2026
Minnesota Senate Floor Meeting
Transcript Highlights:
- It's the 340B drug which is bipartisan. It's the 340B drug pricing<00:01:22.640><c> program.
- What would the attorney general do?
- What would the attorney<00:02:17.599><c> general</c><00:02:18.080><c> do?</c> attorney general do?
- attorney general do?
- </c> prices on all drugs covered by Medicare. prices on all drugs covered by Medicare.
TX
Transcript Highlights:
- In 2023, HRSA reported that just 10 drugs, all specialty drugs, comprise more than a third of the total
- So why are drugs so expensive?
- It's a program where a drug manufacturer sells a drug at $1,000, let's just call it.
- If this drug is eligible per the 340B program, and that's up to the manufacturer of the drug if they
- than non-340B drugs.
Bills:
HB712 , HB722 , HB946 , HB1687 , HB1809 , HB1899 , HB2528 , HB2583 , HB2741 , HB2750 , HB3021 , HB3150 , HB3265 , HB3658 , HB3812 , HB3960 , HB4392 , HB4432
Committee:
House Insurance
CA
California 2025-2026 Regular Session
Senate Business, Professions and Economic Development Committee Apr 6th, 2026
Business, Professions and Economic Development
Transcript Highlights:
- We did this, frankly, with generics.
- For example, a new drug, Yuflyma?
- There are biosimilars, which are roughly equivalent to generic drugs, and then there are... ...to generic
- equivalent of that drug.
- Generic equivalent of that drug. Now, presumably, physicians know this.
MO
Transcript Highlights:
- generics.
- In January of 2025, a second interim report by the FTC focused on specialty generic drugs, finding that
- drug, at $10.
- And keep in mind, most drugs are generics. They're $2, $4, and you have a $25 copay.
- My neighboring pharmacy that was there for 60 years, Winkleman's Drugs, five generations of pharmacies
Committee:
House Health and Mental Health
Summary:
The committee first took testimony on House Bill 1681, which would require health carriers and pharmacy benefit managers to count amounts paid by or on behalf of an enrollee for certain medications toward out-of-pocket maximums when no generic substitute is available. The sponsor described the bill as helping patients with serious illnesses afford needed drugs. The committee then adopted a substitute that rolled HB 1681 together with House Bills 1941 and 2279, including an ERISA-related labor exemption, and passed the combined committee substitute by a vote of 15-2.
The committee next heard House Bill 2365, which was also combined with related bills through a substitute that changed terminology to “delivery systems.” That substitute was adopted by voice vote, and the House Committee substitute for House Bills 2365, 2490, and 2249 was then approved unanimously, 18-0. After that, the committee heard House Bill 2149, the dementia care coordinator bill. The sponsor and supporters from the Alzheimer’s Association and family caregivers argued the state needs a central point person to coordinate resources, improve early detection, support caregivers, and connect rural residents to services. Members raised concerns about the fiscal note, whether the work duplicates existing Area Agencies on Aging and Alzheimer’s Association services, and whether two FTEs would be effective statewide. No vote was taken on HB 2149 during the portion provided.
The committee also heard House Bill 2309, which would prohibit Missouri insurance coverage for organ transplants or related services involving organs taken from prisoners of conscience in China. The sponsor and supporters framed the bill as a human-rights measure aimed at condemning organ harvesting and abuse of Falun Gong practitioners and other prisoners of conscience. Members asked whether there was documentation of such transplants in Missouri and whether federal oversight exists; the sponsor said there is no reporting mechanism and no known opposition. No action was taken on the bill in the excerpt.
Finally, the committee began testimony on House Bills 1975 and 1850, pharmacy benefit manager reform bills. The sponsors said the measures are intended to protect local pharmacies, improve transparency, limit harmful audit practices, and create a critical access pharmacy program. Supporters, including a pharmacy business group, argued PBM practices drive up drug costs and close pharmacies. Opponents, including a carpenters’ health plan representative, warned the bills could increase costs for self-funded plans, limit network and mail-order arrangements, and shift more administrative burden onto plan sponsors. The hearing continued with questions and testimony, but no final vote is shown in the provided transcript.
MA
Massachusetts 2025-2026 Regular Session
Public Health Effects of Xylazine Feb 9th, 2026
Transcript Highlights:
- Xylazine as an animal drug is inexpensive.
- However, the prevalence of similar veterinary drugs and other drug supply contaminants appear to be increasing
- Because we also find that people who use drugs may encounter other drugs.
- of the changes in the drug supply.
- drug that they thought it was.
Summary:
The special commission on xylazine met virtually, called to order by House Chair Mindy Domb, with a quorum present. The commission approved the minutes from its December 11 public meeting and then reviewed the first draft of its final report, which is due to the Legislature by March 30, 2026. Staff explained the report structure, including a commission overview, findings and recommendations from each working group, and appendices with meeting materials and public resources. Commissioners discussed the distinction between licit veterinary xylazine and illicit xylazine in the drug supply, noting that the illicit supply is generally not diverted from legal veterinary sources but obtained through online vendors, and they clarified that xylazine is already classified in Massachusetts as a Schedule 6 substance, so the policy question is whether additional scheduling or penalties are warranted.
For the best practices and enforcement section, staff recommended stronger guidance on secure storage and recordkeeping for authorized users, better reporting of diversion, theft, and suspicious orders, and focused enforcement on illicit production and fentanyl trafficking rather than individual possession. Commissioners suggested adding coordination among public safety, law enforcement, and the Attorney General’s office, as well as a state-level approach to emerging drug threats. In the outreach and treatment section, the draft emphasized that existing harm reduction, wound care, naloxone, and mobile outreach programs are effective but need broader coordination, more trauma-informed care, and better education for providers and first responders. Commissioners raised concerns about provider familiarity with xylazine, the need for first responders to include fire personnel and EMS, and the importance of not turning away people with xylazine-related wounds from recovery or treatment settings.
The education and training section identified four target audiences: first responders, clinicians, non-clinicians in treatment and outreach settings, and people who use drugs and their families. The draft recommended tailored, stigma-free training and educational materials for each group, with consistent updates, continuing education credits where appropriate, and better access to centralized, real-time data on xylazine and other emerging contaminants. Commissioners discussed the need for centralized reporting and public health surveillance, including existing tools like the BSAS dashboard and StreetCheck, and several members urged the commission to recommend a DPH task force or similar body to monitor future drug supply threats. The meeting ended with staff outlining next steps: a revised draft would be circulated by the end of the week, feedback would be incorporated into a second draft by March 2, and the commission planned to vote on the final report at its March 9 meeting, with a backup meeting later in March if needed.
MA
Massachusetts 2025-2026 Regular Session
Joint Committee on Mental Health, Substance Use and Recovery Jun 21st, 2026 at 11:00 am
Joint Committee on Mental Health, Substance Use and Recovery
Transcript Highlights:
- use versus reducing drug use versus promoting drug use or preventing drug use.
- So OPCs don't necessarily increase drug use or attract drug users, but it is a place to deal with drug
- drug testing.
- drug testing.
- On the issue of liability, it is generally a crime to be in the presence of scheduled drugs or narcotics
Summary:
The Joint Committee on Mental Health, Substance Use, and Recovery held a public hearing on several harm reduction bills, including measures to decriminalize simple possession and paraphernalia, authorize overdose prevention centers, and expand access to naloxone for first responders. Chair Mindy Domb and Senator John Velis opened by describing harm reduction as an evidence-based public health strategy and noting Massachusetts’ recent decline in fatal overdoses. They emphasized that testimony would help shape whether and how the bills advance, and explained the hearing process, including time limits and written testimony.
Testimony was sharply divided. Supporters, including Rep. Kate Donaghue, Sen. Cindy Friedman, Rep. Marjorie Decker, Rep. Manny Cruz, public health professionals, recovery advocates, and people with lived experience, argued that harm reduction saves lives, reduces stigma, and can connect people to treatment. They supported overdose prevention centers and decriminalization as tools to keep people alive long enough to enter recovery, and several speakers described personal losses to overdose or family experiences with addiction. Some supporters also framed the bills as racial justice measures, arguing that criminal penalties for possession have disproportionately harmed Black and brown communities.
Opponents, including Sen. Nick Collins and several South End residents, argued that overdose prevention centers and decriminalization would worsen public drug use, crime, and neighborhood disorder, especially around Mass and Cass. They said current approaches such as Section 35, diversion, and police leverage into treatment are more effective, and they urged more treatment beds and recovery facilities instead of harm reduction sites. Committee members questioned witnesses about research, local siting, crime data, and the relationship between harm reduction and treatment, and several members said neighborhood impacts must be considered alongside overdose prevention. The committee did not take a vote during the hearing; it continued receiving testimony and announced a later break before resuming on H. 2196 and S. 1393.